Avastin Biosimilars Market Overview
Avastin® (bevacizumab) is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche.
Read More: https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin® was first approved for treatment of advanced colon cancer (2004); since then, the drug has been approved for advanced lung cancers (2006), metastatic breast cancers (2008), kidney cancers and brain (glioblastoma) cancers (2009). Presently, it is considered an important standard of care in oncology.
Avastin® (bevacizumab) is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche.
Read More: https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin® was first approved for treatment of advanced colon cancer (2004); since then, the drug has been approved for advanced lung cancers (2006), metastatic breast cancers (2008), kidney cancers and brain (glioblastoma) cancers (2009). Presently, it is considered an important standard of care in oncology.
Avastin Biosimilars Market Overview
Avastin® (bevacizumab) is VEGF-A targeting, humanized monoclonal antibody-based therapeutic developed by Genentech and Roche.
Read More: https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
It was the first angiogenesis inhibitor drug to be approved by the US FDA. Avastin® was first approved for treatment of advanced colon cancer (2004); since then, the drug has been approved for advanced lung cancers (2006), metastatic breast cancers (2008), kidney cancers and brain (glioblastoma) cancers (2009). Presently, it is considered an important standard of care in oncology.
0 Comments
0 Shares